Evaluation of oxidative stress in children with congenital heart defects

Pediatrics International

Volumn 54, Issue 1, 2012, Pages 94-98

  Pirinccioglu, Ayfer Gözü ^a   Alyan, Ömer ^a   Kizil, Göksel ^a   Kangin, Murat ^b   Beyazit, Nurcan ^a  

^a DICLE UNIVERSITY   (Turkey)

^b State Hospital   (Turkey)

Author keywords

acute phase reactants; children; congenital heart disease; cytokines; oxidative stress

Indexed keywords

C REACTIVE PROTEIN; CARBONYL DERIVATIVE; FIBRINOGEN; INTERLEUKIN 6; MALONALDEHYDE; TUMOR NECROSIS FACTOR ALPHA;

ACROCYANOSIS; ANTIOXIDANT ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; CYANOSIS; FEMALE; HUMAN; INFANT; LABORATORY TEST; LUNG ARTERY PRESSURE; MALE; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIORITY JOURNAL;

ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHILD; CYTOKINES; FEMALE; FIBRINOGEN; HEART DEFECTS, CONGENITAL; HUMANS; INTERLEUKIN-6; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PROTEIN CARBONYLATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857204198     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2011.03478.x     Document Type: Article

References (48)

1. Mueller CF, Laude K, McNally JS, Harrison DG,. ATVB in focus: redox mechanisms in blood vessels. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 274-8. (Pubitemid 40189145)
2. Lefer DJ, Granger DN,. Oxidative stress and cardiac disease. Am. J. Med. 2000; 109: 315-23.
3. Madamanchi NR, Vendrov A, Runge MS,. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 29-38. (Pubitemid 40054251)
4. Cai H, Harrison DG,. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 2000; 87: 840-4.
5. Leopold JA, Loscalzo J,. Oxidative enzymopathies and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1332-40.
6. Stocker R, Keaney JF Jr,. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004; 84: 1381-478. (Pubitemid 39302636)
7. Taniyama Y, Griendling KK,. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42: 1075-81. (Pubitemid 37549058)
8. Zalba G, San Jose G, Moreno MU, et al,. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001; 38: 1395-9. (Pubitemid 34033422)
9. Mates JM, Perez-Gomez C, Olalla L, Segura JM, Blanca M,. Allergy to drugs: antioxidant enzymic activities, lipid peroxidation and protein oxidative damage in human blood. Cell Biochem. Funct. 2000; 18: 77-84. (Pubitemid 30312588)
10. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A,. Biomarkers of oxidative damage in human disease. Clin. Chem. 2006; 52: 601-23.
11. Levine RL, Garland D, Oliver CN, et al,. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990; 186: 464-78. (Pubitemid 20279989)
12. Paoletti R, Gotto MA, Hajjar DP,. Inflammation in atherosclerosis and implications for therapy. Circulation 2004; 109 (23 Suppl. 1): III20-6. (Pubitemid 38786439)
13. Ungvari Z, Parrado-Fermamdez C, Csoszar A, de Caba R,. Mechanisms underlying caloric restriction and lifespan regulation. Implication for vascular aging. Circ. Res. 2008; 102: 519-28.
14. Fung TT, Rexrode KM, Mantzoros CS, Manson JE, Willett WC, Hu FB,. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation 2009; 119: 1093-100.
15. Konhilas JP, Leinwand LA,. The effect of biological sex and diet on the development of heart failure. Circulation 2007; 116: 2747-59. (Pubitemid 350291247)
16. Romero JC, Reckelhoff JF,. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34: 943-9. (Pubitemid 29501328)
17. Redon J, Oliva MR, Tormos C, et al,. Antioxidant activities and oxidative byproducts in human hypertension. Hypertension 2003; 41: 1096-2001.
18. Murray CJL, Lopez AD,. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42. (Pubitemid 27212192)
19. Pirinccioglu AG, Gökalp D, Pirinccioglu M, Kizil G, Kizil M,. Malondialdehyde (MDA) and protein carbonyl (PCO) levels as biomarkers of oxidative stress in subjects with familial hypercholesterolemia. Clin. Biochem. 2010; 43: 1220-4.
20. Rokicki W, Strzalkowski A, Klapcinska B, Danch A, Sobczak A,. Antioxidant status in newborns and infants suffering from congenital heart defects. Wiad. Lek. 2003; 56: 337-40.
21. Ercan S, Cakmak A, Kosecik M, Erel O,. The oxidative state of children with cyanotic and acyanotic congenital heart disease. Anadolu Kardiyol. Derg. 2009; 9: 486-90.
22. Hoffman JI, Kaplan S,. The incidence of congenital heart disease. J. Am. Coll. Cardiol. 2002; 39: 1890-900. (Pubitemid 34628268)
23. Samanek M,. Congenital heart malformations: prevalence, severity, survival, and quality of life. Cardiol. Young 2000; 10: 179-85.
24. Nouri S,. Congenital heart defects: cyanotic and acyanotic. Pediatr. Ann. 1997; 26 (2): 95-8.
25. Otto CM,. Textbook of Clinical Echocardiography. Elsevier-Saunders, Philadelphia, PA, 1995.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ,. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951; 193: 265-75.
27. Buege JA, Aust JD,. Microsomal lipid peroxidation. Methods Enzymol. 1978; 52: 302-10.
28. Erel O,. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin. Biochem. 2004; 37: 112-9. (Pubitemid 38077161)
29. Madamanchi NR, Vendrov A, Runge M,. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 29-38. (Pubitemid 40054251)
30. Stocker R, Keaney JF Jr,. New insights on oxidative stress in the artery wall. J. Thromb. Haemost. 2005; 3: 1825-34. (Pubitemid 41716569)
31. Yilmaz E, Ustundag B, Sen Y, Akarsu S, Kurt AN, Dogan Y,. The levels of Ghrelin, TNF-alpha, and IL-6 in children with cyanotic and acyanotic congenital heart disease. Mediators Inflamm. 2007; 32403, doi:10.1155/2007/32403. (Pubitemid 47388730)
32. Inui A,. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 1999; 59: 4493-501. (Pubitemid 29428945)
33. Kotler DP,. Cachexia. Ann. Intern. Med. 2000; 133: 622-34.
34. Freeman LM, Roubenoff R,. The nutrition implications of cardiac cachexia. Nutr. Rev. 1994; 52: 340-7. (Pubitemid 24349551)
35. Morrison WL, Edwards RHT,. Cardiac cachexia. Br. Med. J. 1991; 302: 301-2.
36. Rosenthal A,. Nutritional considerations in the prognosis treatment of children with congenital heart disease. In:, Suskind RM, Levinter-Suskind L, (eds). Textbook of Pediatric Nutrition. Raven Press, New York, 1993; 383-91.
37. McMurray J, Abdullah I, Dargie HJ, Shapiro D,. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br. Heart J. 1991; 66: 356-8.
38. Schwarz KB,. Oxidative stress during viral infection: a review. Free Radic. Biol. Med. 1996; 21: 641-9. (Pubitemid 26331094)
39. Du Clos TW,. Function of C-reactive protein. Ann. Med. 2000; 32: 274-8. (Pubitemid 30311864)
40. Loukovaara M, Leinonen P, Teramo K, Alfthan H, Stenman UH, Andersson S,. Fetal hypoxia is associated with elevated cord serum C-reactive protein levels in diabetic pregnancies. Biol. Neonate 2004; 85: 237-42. (Pubitemid 38812997)
41. Charuruks N, Laohajinda B, Rujiwantigum S, Chaiworaporn M,. Reference value for C-reactive protein and its distribution pattern in Thai adults. Circ. J. 2005; 69: 339-44. (Pubitemid 40410192)
42. Pepys MB, Berger A,. The renaissance of C reactive protein: it maybe a marker not only of acute illness but also of future cardiovascular disease. BMJ 2001; 322: 4-5.
43. Pearson TA, Mensah GA, Alexander RW, et al,. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and American heart association. Circulation 2003; 107: 499-511. (Pubitemid 36158056)
44. Verma S, Li SH, Badiwala MV, et al,. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890-6. (Pubitemid 34437614)
45. Verma S, Kuliszewski MA, Li SH, et al,. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109: 2058-67. (Pubitemid 38620212)
46. Yin WH, Chen JW, Jen HL, et al,. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am. Heart J. 2004; 147: 931-8.
47. Anand IS, Latini R, Florea VG, et al,. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005; 112: 1428-34. (Pubitemid 41291768)
48. Ileri M, Buyukasik Y, Ileri NS, et al,. Activation of blood coagulation in patients with mitral stenosis and sinus rhythm. Am. J. Cardiol. 1998; 81: 795-7. (Pubitemid 28146464)